中國創意控股(08368.HK)配股事項失效
格隆匯 7 月 31日丨中國創意控股(08368.HK)公佈,有關擬向倆股東溢價8.91%配發9091萬股事項,根據認購協議,倘有任何條件於截止日期(即2020年7月31日)或公司與認購人可能書面協定的其他較後日期之前未獲達成,認購協議將予終止,而公司及認購人將自動免除認購協議項下所有義務,惟各訂約方先前違反的任何責任除外。
由於認購協議中的若干條件尚未在截止日期之前達成,及公司及認購人並未延長截止日期,因此認購協議已根據其條款在2020年7月31日失效,並且將不再具有效力,而公司及認購人將自動免除認購協議項下所有義務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.